Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models

Autores
Rico, Maria Jose; Baglioni, María Virginia; Bondarenko, Maryna; Laluce, Nahuel Cesatti; Rozados, Viviana Rosa; André, Nicolas; Carré, Manon; Scharovsky, Olga Graciela; Menacho Márquez, Mauricio Ariel
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.
Fil: Rico, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: Baglioni, María Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: Bondarenko, Maryna. Aix-Marseille Université; Francia
Fil: Laluce, Nahuel Cesatti. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: André, Nicolas. Aix-Marseille Université; Francia. Service d'Hématologie and Oncologie Pédiatrique; Francia. Metronomics Global Health Initiative; Francia
Fil: Carré, Manon. Aix-Marseille Université; Francia
Fil: Scharovsky, Olga Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina. Metronomics Global Health Initiative; Francia
Fil: Menacho Márquez, Mauricio Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Materia
BREAST CANCER
DRUG REPOSITIONING
METFORMIN
METRONOMICS
PROPRANOLOL
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/66525
Acceder
id CONICETDig_1029bb903856eff8371a9149d60c8767
oai_identifier_str oai:ri.conicet.gov.ar:11336/66525
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer modelsRico, Maria JoseBaglioni, María VirginiaBondarenko, MarynaLaluce, Nahuel CesattiRozados, Viviana RosaAndré, NicolasCarré, ManonScharovsky, Olga GracielaMenacho Márquez, Mauricio ArielBREAST CANCERDRUG REPOSITIONINGMETFORMINMETRONOMICSPROPRANOLOLhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.Fil: Rico, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; ArgentinaFil: Baglioni, María Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; ArgentinaFil: Bondarenko, Maryna. Aix-Marseille Université; FranciaFil: Laluce, Nahuel Cesatti. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; ArgentinaFil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; ArgentinaFil: André, Nicolas. Aix-Marseille Université; Francia. Service d'Hématologie and Oncologie Pédiatrique; Francia. Metronomics Global Health Initiative; FranciaFil: Carré, Manon. Aix-Marseille Université; FranciaFil: Scharovsky, Olga Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina. Metronomics Global Health Initiative; FranciaFil: Menacho Márquez, Mauricio Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; ArgentinaImpact Journals LLC2017-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/66525Rico, Maria Jose; Baglioni, María Virginia; Bondarenko, Maryna; Laluce, Nahuel Cesatti; Rozados, Viviana Rosa; et al.; Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models; Impact Journals LLC; Oncotarget; 8; 2; 1-2017; 2874-28891949-2553CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.13760info:eu-repo/semantics/altIdentifier/url/http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13760&path[]=43751info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:06:57Zoai:ri.conicet.gov.ar:11336/66525instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:06:57.595CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
spellingShingle Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
Rico, Maria Jose
BREAST CANCER
DRUG REPOSITIONING
METFORMIN
METRONOMICS
PROPRANOLOL
title_short Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_full Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_fullStr Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_full_unstemmed Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
title_sort Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
dc.creator.none.fl_str_mv Rico, Maria Jose
Baglioni, María Virginia
Bondarenko, Maryna
Laluce, Nahuel Cesatti
Rozados, Viviana Rosa
André, Nicolas
Carré, Manon
Scharovsky, Olga Graciela
Menacho Márquez, Mauricio Ariel
author Rico, Maria Jose
author_facet Rico, Maria Jose
Baglioni, María Virginia
Bondarenko, Maryna
Laluce, Nahuel Cesatti
Rozados, Viviana Rosa
André, Nicolas
Carré, Manon
Scharovsky, Olga Graciela
Menacho Márquez, Mauricio Ariel
author_role author
author2 Baglioni, María Virginia
Bondarenko, Maryna
Laluce, Nahuel Cesatti
Rozados, Viviana Rosa
André, Nicolas
Carré, Manon
Scharovsky, Olga Graciela
Menacho Márquez, Mauricio Ariel
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BREAST CANCER
DRUG REPOSITIONING
METFORMIN
METRONOMICS
PROPRANOLOL
topic BREAST CANCER
DRUG REPOSITIONING
METFORMIN
METRONOMICS
PROPRANOLOL
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.
Fil: Rico, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: Baglioni, María Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: Bondarenko, Maryna. Aix-Marseille Université; Francia
Fil: Laluce, Nahuel Cesatti. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
Fil: André, Nicolas. Aix-Marseille Université; Francia. Service d'Hématologie and Oncologie Pédiatrique; Francia. Metronomics Global Health Initiative; Francia
Fil: Carré, Manon. Aix-Marseille Université; Francia
Fil: Scharovsky, Olga Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina. Metronomics Global Health Initiative; Francia
Fil: Menacho Márquez, Mauricio Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
description Discovery of new drugs for cancer treatment is an expensive and time-consuming process and the percentage of drugs reaching the clinic remains quite low. Drug repositioning refers to the identification and development of new uses for existing drugs and represents an alternative drug development strategy. In this work, we evaluated the antitumor effect of metronomic treatment with a combination of two repositioned drugs, metformin and propranolol, in triple negative breast cancer models. By in vitro studies with five different breast cancer derived cells, we observed that combined treatment decreased proliferation (P < 0.001), mitochondrial activity (P < 0.001), migration (P < 0.001) and invasion (P < 0.001). In vivo studies in immunocompetent mice confirmed the potential of this combination in reducing tumor growth (P < 0.001) and preventing metastasis (P < 0.05). Taken together our results suggest that metformin plus propranolol combined treatment might be beneficial for triple negative breast cancer control, with no symptoms of toxicity.
publishDate 2017
dc.date.none.fl_str_mv 2017-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/66525
Rico, Maria Jose; Baglioni, María Virginia; Bondarenko, Maryna; Laluce, Nahuel Cesatti; Rozados, Viviana Rosa; et al.; Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models; Impact Journals LLC; Oncotarget; 8; 2; 1-2017; 2874-2889
1949-2553
CONICET Digital
CONICET
url http://hdl.handle.net/11336/66525
identifier_str_mv Rico, Maria Jose; Baglioni, María Virginia; Bondarenko, Maryna; Laluce, Nahuel Cesatti; Rozados, Viviana Rosa; et al.; Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models; Impact Journals LLC; Oncotarget; 8; 2; 1-2017; 2874-2889
1949-2553
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.13760
info:eu-repo/semantics/altIdentifier/url/http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=13760&path[]=43751
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Impact Journals LLC
publisher.none.fl_str_mv Impact Journals LLC
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269983062622208
score 13.13397

Publicaciones similares